HDAC7 (human, recombinant)

Histone deacetylase 7 (HDAC7) is a zinc-dependent metalloenzyme and class IIa HDAC. It is composed of an N-terminal regulatory domain, which contains a myocyte-specific enhancer factor 2 (MEF2) binding site, three 14-3-3 binding sites, and a nuclear localization signal, a catalytic domain, and a C-terminal domain that contains a nuclear export signal. HDAC7 shuttles between the cytoplasm, mitochondria, and nucleus and is expressed in the heart, placenta, pancreas, lungs, and skeletal muscle. It acts as a transcriptional corepressor and has many binding partners, including MEF2, nuclear receptor co-repressor (NCOR), and hypoxia-inducible factor-1alpha (HIF-1alpha), and its enzymatic activity is dependent on association with HDAC3. HDAC7 is involved in immunity, angiogenesis, embryonic development, muscle cell differentiation, and apoptosis. Knockdown of HDAC7 inhibits sphere formation of breast cancer stem cells (CSCs) in vitro. Hdac7-/- is embryonic lethal and induces hemorrhages, pericardial effusion, and enlarged dorsal aortae in mice. Expression of HDAC7 is increased in patients with various cancers and is associated with poor prognosis. Cayman's HDAC7 (human, recombinant) protein can be used for enzyme activity assays.Synonyms: Histone Deacetylase 7. Purity: >56% estimated by SDS-PAGE. Source: Active recombinant human N-terminal GST-tagged HDAC7 expressed in insect cells. Amino Acids: 518-952. MW: 78 kDa. Storage Buffer: 40 mM Tris-HCl, pH 8.0, 250 mM sodium chloride, and 20% glycerol. UniProt Accession No: Q8WUI4.